

Please amend Claims 1, 17-19 and 41-44 . Amendments to the claims are indicated in the attached "Marked Up Version of Amendments" (pages i - ii).

- E¹
1. (Thrice Amended) A fusion molecule consisting of (a) a peptide consisting of amino acids 12 to 88 of the hepatitis delta antigen (HDAg) or a fragment thereof that forms a coil and (b) at least one binding moiety.
-
17. (Twice Amended) An isolated and purified fusion molecule consisting of:
- (a) a polypeptide having an amino acid sequence selected from the group consisting of an amino acid sequence selected from the group consisting of SEQ ID NOS:1-8, amino acids 12 - 48 of SEQ ID NOS:1-8, amino acids 12 - 60 of SEQ ID NOS:1-8, SEQ ID NO:9 , SEQ ID NO:11, amino acids 12 - 48 of SEQ ID NO:11, amino acids 12 - 60 of SEQ ID NO:11, SEQ ID NOS:15-17, SEQ ID NOS:18-20, SEQ ID NO:25, and fragments thereof which form a coiled-coil oligomer and
- E²
- (b) at least one binding moiety.
18. (Amended) A peptide consisting of amino acids 12 to 88 of the hepatitis delta antigen (HDAg) wherein a serine residue is substituted with cysteine.
19. (Amended) An isolated and purified molecule comprising a polypeptide consisting of an amino acid sequence of amino acids 12 - 88 of HDAg, or a fragment thereof which forms a coiled-coil oligomer and a nuclear localization signal.
-
- E³
41. (Amended) A method of binding binding partners comprising contacting a fusion molecule of Claim 1 having a first binding moiety with a second binding moiety, wherein the first and second moieties are binding partners, under conditions suitable for binding.